Geneva, May 20 -- International Clinical Trials Registry received information related to the study (NCT06961630) titled 'Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk' on May 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: NYU Langone Health
Condition:
Myocardial Injury After Noncardiac Surgery
Intervention:
Drug: Rivaroxaban
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: June 1, 2025
Target Sample Size: 50
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT06961630
Disclaimer: ...